Eisai to Present New Five-Year Lecanemab Data and Real-World Alzheimer's Disease Research at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Eisai Co., Ltd. announced today that it will present new Alzheimer's disease (AD) research at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place November 16-19, 2026, in Boston and online.